An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder

Charles Pinto, J. K. Trivedi, G. K. Vankar, P. S.V.N. Sharma, Vikram Narasimha

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To evaluate the tolerability and response to escitalopram in Indian patients with major depression, over an 8-week open-label multicentric study was carried out among 18-65 years old Indian patients suffering from DSM IV major depressive disorder with Montgomery-Asberg depression rating scale (MADRS) total score≥22. Patients received a fixed dose of escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks. Patients were evaluated for depression and rated on MADRS score and clinical global impressions-severity (CGI-S) and - improvement (CGI-I) scores. They were monitored for treatment-emergent adverse effects. A total of 119 patients were enrolled and 103 completed the trial. There was a decrease from baseline in the MADRS total score after one week of treatment continuing until 8 weeks. By week 8, 76.9% patients had responded to treatment (≥50% or more reduction of MADRS total score). A similar pattern of improvement to that seen with the MADRS total score was seen with CGI-S and CGI-I scores. Escitalopram was well tolerated, with only 2 patients (1.7%) withdrawing from the study due to adverse events. There were no serious adverse events.

Original languageEnglish
JournalJournal of the Indian Medical Association
Volume105
Issue number7
Publication statusPublished - 01-07-2007
Externally publishedYes

Fingerprint

Citalopram
Major Depressive Disorder
Depression
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Pinto, Charles ; Trivedi, J. K. ; Vankar, G. K. ; Sharma, P. S.V.N. ; Narasimha, Vikram. / An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. In: Journal of the Indian Medical Association. 2007 ; Vol. 105, No. 7.
@article{69694882a40c485895167c028e3e1f5e,
title = "An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder",
abstract = "To evaluate the tolerability and response to escitalopram in Indian patients with major depression, over an 8-week open-label multicentric study was carried out among 18-65 years old Indian patients suffering from DSM IV major depressive disorder with Montgomery-Asberg depression rating scale (MADRS) total score≥22. Patients received a fixed dose of escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks. Patients were evaluated for depression and rated on MADRS score and clinical global impressions-severity (CGI-S) and - improvement (CGI-I) scores. They were monitored for treatment-emergent adverse effects. A total of 119 patients were enrolled and 103 completed the trial. There was a decrease from baseline in the MADRS total score after one week of treatment continuing until 8 weeks. By week 8, 76.9{\%} patients had responded to treatment (≥50{\%} or more reduction of MADRS total score). A similar pattern of improvement to that seen with the MADRS total score was seen with CGI-S and CGI-I scores. Escitalopram was well tolerated, with only 2 patients (1.7{\%}) withdrawing from the study due to adverse events. There were no serious adverse events.",
author = "Charles Pinto and Trivedi, {J. K.} and Vankar, {G. K.} and Sharma, {P. S.V.N.} and Vikram Narasimha",
year = "2007",
month = "7",
day = "1",
language = "English",
volume = "105",
journal = "Journal of the Indian Medical Association",
issn = "0019-5847",
publisher = "Indian Medical Association",
number = "7",

}

An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. / Pinto, Charles; Trivedi, J. K.; Vankar, G. K.; Sharma, P. S.V.N.; Narasimha, Vikram.

In: Journal of the Indian Medical Association, Vol. 105, No. 7, 01.07.2007.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder

AU - Pinto, Charles

AU - Trivedi, J. K.

AU - Vankar, G. K.

AU - Sharma, P. S.V.N.

AU - Narasimha, Vikram

PY - 2007/7/1

Y1 - 2007/7/1

N2 - To evaluate the tolerability and response to escitalopram in Indian patients with major depression, over an 8-week open-label multicentric study was carried out among 18-65 years old Indian patients suffering from DSM IV major depressive disorder with Montgomery-Asberg depression rating scale (MADRS) total score≥22. Patients received a fixed dose of escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks. Patients were evaluated for depression and rated on MADRS score and clinical global impressions-severity (CGI-S) and - improvement (CGI-I) scores. They were monitored for treatment-emergent adverse effects. A total of 119 patients were enrolled and 103 completed the trial. There was a decrease from baseline in the MADRS total score after one week of treatment continuing until 8 weeks. By week 8, 76.9% patients had responded to treatment (≥50% or more reduction of MADRS total score). A similar pattern of improvement to that seen with the MADRS total score was seen with CGI-S and CGI-I scores. Escitalopram was well tolerated, with only 2 patients (1.7%) withdrawing from the study due to adverse events. There were no serious adverse events.

AB - To evaluate the tolerability and response to escitalopram in Indian patients with major depression, over an 8-week open-label multicentric study was carried out among 18-65 years old Indian patients suffering from DSM IV major depressive disorder with Montgomery-Asberg depression rating scale (MADRS) total score≥22. Patients received a fixed dose of escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks. Patients were evaluated for depression and rated on MADRS score and clinical global impressions-severity (CGI-S) and - improvement (CGI-I) scores. They were monitored for treatment-emergent adverse effects. A total of 119 patients were enrolled and 103 completed the trial. There was a decrease from baseline in the MADRS total score after one week of treatment continuing until 8 weeks. By week 8, 76.9% patients had responded to treatment (≥50% or more reduction of MADRS total score). A similar pattern of improvement to that seen with the MADRS total score was seen with CGI-S and CGI-I scores. Escitalopram was well tolerated, with only 2 patients (1.7%) withdrawing from the study due to adverse events. There were no serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=38749119061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749119061&partnerID=8YFLogxK

M3 - Article

VL - 105

JO - Journal of the Indian Medical Association

JF - Journal of the Indian Medical Association

SN - 0019-5847

IS - 7

ER -